Home Tags Drug Development

Drug Development Related Content

non communicable diseases in africa, endocrine disruptors

Endocrine disruptors and non-communicable diseases in Africa

Chiara Frazzoli and Alberto Mantovani from Istituto Superiore di Sanità share their insights into endocrine disruptors and non-communicable diseases in Africa, in collaboration with NOODLES Alliance Network.
antimicrobial adhesive, healthcare-associated infection

FLEXPOL: An antimicrobial adhesive film

The EU-funded project FLEXPOL (GA number 721062) offers an affordable approach to prohibit the spread of bacteria and healthcare-associated infections using cost-effective and sustainable film products.
research into osteoarthritis, clinical research

Impact and early intervention: Clinical research into osteoarthritis

Versus Arthritis speaks to award-winning rheumatologist Dr Fiona Watt about clinical research into osteoarthritis.
clinical contact research

Clinical Contract Research: Building the digital bridge between clinical research and clinical care

Prof Dr Freimut Schliess, Director, Science & Innovation at Profil GmbH, sheds light on how Clinical Contract Research Organisations are building the digital bridge connecting clinical research and clinical care.
fda approval, new drug

How can you improve your chances of FDA approval?

Here Dr. Harneet Arora, freelance neurologist, and FDA regulations expert, shares her advice on how to submit an application with FDA approval.
Type 1 diabetes treatment

Charities renew investment in Type 1 diabetes treatment

Diabetes UK and JDRF have announced their continued commitment to revolutionising Type 1 diabetes treatment, by awarding £490,000 to fund the next generation of immunotherapy research.
heart failure treatment, erectile dysfunction

Sex drug could be the next heart failure treatment

The University of Manchester found that a drug used for erectile dysfunction can slow or even reverse the progression of heart failure of sheep.
medical cannabis products

Five-year license issued to “Pharma Essenza Cannabis SA” and “PENTE SA”

A five-year license has been issued to two companies allowing the cultivation and processing of medical cannabis products.
treatment for psychosis, cbd oil

CBD could be “new class of treatment” for psychosis

King's College London researchers found that cannabidiol (CBD) could hold promise as a treatment for psychosis, according to reasonable benefits seen in a clinical trial.
Tackling tuberculosis

Tackling tuberculosis (TB) in Africa

While Africa has made progress in tackling tuberculosis (TB), it still has one of the highest TB rates in the world and remains a priority.
Oxford Cannabinoid Technologies LTD

Oxford Cannabinoid Technologies – Researching new therapies

Oxford Cannabinoid Technologies is a biopharmaceutical company combining cannabinoid medicine with world class scientific research and drug development.
Alzheimer's brain, Alzheimer's disease research

Scientists reveal largest ever map of human Alzheimer’s brain

On the 4th February 2019, a scientific breakthrough for the future of Alzheimer's brain reserach has been published - read on to explore the developments.
UCL Translational office

The Translational Research Office at University College London

UCL’s Translational Research Office (TRO) builds on an increasingly vibrant translational culture across the university community.
opioids for pain, poor areas

GPs prescribe more opioids for pain in poor Northern areas, study reveals

English patients living in poorer areas are likely to be prescribed more opioids for pain by their GPs, according to a study led by University of Manchester and University of Nottingham researchers.
Neuromuscular disease

Advances in newborn screening for neuromuscular disease

Kristin Stephenson, Sr. VP, Chief Policy & Community Engagement Officer at the Muscular Dystrophy Association details the advances taking place in newborn screening for neuromuscular disease
Organoids

Developmental biology: Fulfilling the promise of Organoids

Professor of Developmental Mechanics at the Department of Genetics, University of Cambridge, Alfonso Martinez Arias shares his expert view on Organoids, within the field of developmental biology.
Cancer therapy

The current and future challenges of personalised cancer therapy

Managing Director of The Cancer Drug Development Forum, Prof. H. Zwierzina reveals his opinions on the current and future challenges of personalised cancer therapy, including the need for biomarkers.
drug innovation

ISOTOPICS, a European project for de-risking drug innovation

Christophe Dugave & Karen Hinsinger from CEA-Saclay highlight an exciting European research project for de-risking drug innovation, ISOTOPICS
Heterocyclic

The changing face of Heterocyclic Chemistry in the pharmaceutical industry

Professor of Organic Chemistry at University of York and Chairman of the Royal Society of Chemistry’s Heterocyclic and Synthesis Group, Peter O’Brien explores the role of heterocycles in the pharmaceutical industry In 2017, the Royal Society of Chemistry’s Heterocyclic and Synthesis Group celebrated its 50th anniversary. It thus appears timely...
early drug development

IDEAS: improving design, evaluation and analysis of early drug development studies

Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University explores a novel approach to Ph.D. training for those in the pharmaceutical industry

Follow Open Access Government